Pharmacy Update
Disclaimer: We are getting frequent COVID-related questions about drug concerns and potential interactions. This information is as of July 2, 2020. We will do our best to keep you up to date with this ever evolving situation. This is the most update information at the time of publication.
Note: There are no Food and Drug Administration
(FDA) approved therapies for treatment or prevention of COVID-19. If at all possible, it is best to have patients enrolled in a clinical trial.
In this issue:
UPDATE: NIH TREATMENT GUIDELINES PANEL RECOMMENDATIONS FOR DEXAMETHASONE IN COVID-19 PATIENTS
Preliminary data published from the RECOVERY
1 (Randomized Evaluation of COVid-19 thERapY) trial showed an all-cause mortality benefit (primary outcome measure) for the patients who were requiring oxygen or mechanical ventilation and were randomized to receive dexamethasone compared to those who received standard of care.
COLCHICINE FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
The results of a prospective, open-label, randomized trial involving colchicine that was conducted in multiple hospitals in Greece was published in JAMA.
1
